

Pembrolizumab KEYNOTE-181

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments



Pembrolizumab KEYNOTE-181

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: Locally advanced or metastatic oesophageal or OGJ carcinoma that is not amenable to surgical resection or definitive CRT after ≥1 prior lines of systemic therapy for patients with tumours of squamous cell histology that express PD-L1 (CPS ≥10)

Experimental Arm: Pembrolizumab

Control Arm: Chemotherapy



